LAUSR

&NA; Gammadelta T (&ggr;&dgr;T) lymphocytes have provoked interest in oncology, particularly as regards their potential use in immunotherapy, because of their unique ability to recognise antigens without a requirement for major histocompatibility complex antigen presentation, and to quickly activate an anti‐tumour response. However, work in some cancers has suggested that they also have pro‐tumourigenic activity. Their role in breast cancer is unclear. This review outlines the evidence to date in in vitro studies, in vivo mouse models and in human studies regarding the role of &ggr;&dgr;T lymphocytes in breast cancer. We describe the seemingly opposing roles of the predominantly circulating V&ggr;9V&dgr;2+ subtype, which can suppress tumour growth through direct cytotoxicity, induction of apoptosis and inhibition of angiogenesis, and the predominantly tumour‐infiltrating &ggr;&dgr;1+ subtype which can promote tumour growth and spread through immunosuppressant effects. We summarise the evidence in breast cancer for the mechanisms of action of &ggr;&dgr;T lymphocytes and describe how factors in the tumour microenvironment may affect their function, polarising them towards a pro‐tumourigenic, immune‐suppressing role. We also describe the experience to date of &ggr;&dgr;T lymphocytes in immunotherapy for breast cancer and suggest the direction of work going forward, particularly as regards different breast cancer subtypes.